期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Diuretic Agents in Treatment of Sudden Deafness
1
作者 JI Chang-you LI Hong-tao +4 位作者 zhou ding-rong CHEN Ji-chuan WANG Yi-nan GUAN Li-qian ZHANG Min 《Journal of Otology》 2008年第1期35-38,共4页
Objective To study the role of diuretic agents in treating sudden deafness (SD) and explore the possibility of endolymphatic hydrops as a potential cause of SD. Methods Twenty-eight SD cases were reviewed. In 23 cases... Objective To study the role of diuretic agents in treating sudden deafness (SD) and explore the possibility of endolymphatic hydrops as a potential cause of SD. Methods Twenty-eight SD cases were reviewed. In 23 cases, treatment was initiated with routine agents. Diuretic agents were later added in 8 of these cases that failed to respond to routine treatment agents. Diuretic agents were included in the initial treatment in the rest 5 cases. In total, 13 cases received diuretics in addition to routine treatment agents and 15 cases received conventional treatment only. Results In the 8 cases who received diuretics after failed conventional treatments, 4 showed hearing improvement, whereas all 5 cases in which diuretics were included in the initial treatment demonstrated hearing improvement. Conclusion These results suggest a possible role of endolymphatic hydrops in the pathophysiologic course of SD. Diuretics should be considered when clear indications exist with no conflicts to other medical conditions. 展开更多
关键词 sudden deafness Endolymphatic hydrops DIURETICS
下载PDF
丹参酮ⅡA聚乙二醇-聚己内酯纳米胶束的制备、细胞内分布及减少心肌缺血再灌注损伤的研究 被引量:12
2
作者 王松 汪茂胜 +2 位作者 周定荣 房芳 窦润鹏 《中草药》 CAS CSCD 北大核心 2020年第8期2141-2150,共10页
目的采用薄膜水化法制备丹参酮ⅡA聚乙二醇-聚己内酯(PEG-PCL)纳米胶束,并研究该胶束的细胞内分布及抗心肌缺血再灌注损伤的作用。方法采用正交试验优选丹参酮ⅡAPEG-PCL纳米胶束的制备工艺条件,优选后的丹参酮ⅡA PEG-PCL纳米胶束进行... 目的采用薄膜水化法制备丹参酮ⅡA聚乙二醇-聚己内酯(PEG-PCL)纳米胶束,并研究该胶束的细胞内分布及抗心肌缺血再灌注损伤的作用。方法采用正交试验优选丹参酮ⅡAPEG-PCL纳米胶束的制备工艺条件,优选后的丹参酮ⅡA PEG-PCL纳米胶束进行粒径、Zeta电位和透射电镜检测表征,并进行稳定性评价,以香豆素-6作为荧光探针,评价PEG-PCL纳米胶束在细胞内的摄取及分布,再进行细胞外存留药物实验,验证PEG-PCL纳米胶束促进药物的细胞摄取性能;采用结扎冠状动脉方法构建心肌缺血再灌注损伤大鼠模型,评价丹参酮ⅡAPEG-PCL纳米胶束的药效作用。结果丹参酮ⅡA PEG-PCL纳米胶束的优选工艺条件:丹参酮ⅡA与PEG-PCL投料比为1.2∶10,转速为100 r/min,水化温度为37℃,采用旋蒸方式形成薄膜,然后冷冻干燥除尽有机溶剂,在水化超声形成纳米胶束;优选工艺后的丹参酮ⅡA PEG-PCL纳米胶束粒径为(16.8±0.4)nm,Zeta电位为(-29.8±4.9)m V,载药量为(7.8±0.6)%,包封率为(86.4±5.2)%,稳定性良好;荧光实验表明,PEG-PCL纳米胶束可以促进药物的细胞摄取,进入细胞后,还可将药物聚集在线粒体周围,重合性良好;药效实验结果表明,丹参酮ⅡAPEG-PCL可以明显降低模型动物血清肌酸激酶(CK)、乳酸脱氢酶(LDH)、心肌肌钙蛋白(cTnI)水平,升高超氧化物歧化酶(SOD)水平,减少心肌梗死面积,改善心肌病理变化,这些药效结果均明显优于丹参酮ⅡA。结论丹参酮ⅡA PEG-PCL纳米胶束可以很大程度上提高丹参酮ⅡA的心肌细胞摄取量,并聚集在线粒体周围,增强药物减轻心肌缺血再灌注损伤的作用。 展开更多
关键词 丹参酮ⅡA 聚乙二醇-聚己内酯 纳米胶束 薄膜水化法 线粒体 细胞摄取 细胞内分布 心肌缺血再灌注损伤 正交试验 稳定性评价
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部